ConductScience.org, home

Paper387221

Mechanism of action of cis-dichlorodiammineplatinum(II).

Zwelling LA and 1 other. Cancer Treat Rep, 1979. Cited by 223 papers, by iCite.

Cite this record

ConductScience Library. Mechanism of action of cis-dichlorodiammineplatinum(II). Papers, record 387221. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/387221

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanism of action of cis-dichlorodiammineplatinum(II).
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1979
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
223
iCite
Relative citation ratio, by iCite
7.24
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zwelling LAL A
2Kohn KWK W

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CisplatinMajor topic
Animals
Antineoplastic Agents
Binding Sites
Cross-Linking Reagents
DNA
DNA Repair
Humans
Neoplasms
Structure-Activity Relationship

Source PubMed

Download CSV of topics

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 223 citations.

PMIDTitleJournalYearIn PapersSource
42199066Mitophagy in cisplatin-induced kidney injury: regulatory mechanisms and therapeutic targets.Ann Med2026https://conductscience.org/library/papers/42199066PubMed
39106540Repair of genomic interstrand crosslinks.DNA Repair (Amst)2024https://conductscience.org/library/papers/39106540PubMed
37554969Alkylation of nucleobases by 2-chloro-N,N-diethylethanamine hydrochloride (CDEAH) sensitizes PARP1-deficient tumors.NAR Cancer2023https://conductscience.org/library/papers/37554969PubMed
33622870Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo.In Vivo2021https://conductscience.org/library/papers/33622870PubMed
31221747A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1.Proc Natl Acad Sci U S A2019https://conductscience.org/library/papers/31221747PubMed
27754384Metabolomic Profiling of the Effects of Melittin on Cisplatin Resistant and Cisplatin Sensitive Ovarian Cancer Cells Using Mass Spectrometry and Biolog Microarray Technology.Metabolites2016https://conductscience.org/library/papers/27754384PubMed
27253174Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial.Br J Cancer2016https://conductscience.org/library/papers/27253174PubMed
26427828
Usefulness of Pseudocontinuous Arterial Spin-Labeling for the Assessment of Patients with Head and Neck Squamous Cell Carcinoma by Measuring Tumor Blood Flow in the Pretreatment and Early Treatment Period.
AJNR Am J Neuroradiol2016https://conductscience.org/library/papers/26427828PubMed
26004625Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.Expert Opin Ther Targets2015https://conductscience.org/library/papers/26004625PubMed
25880539A metabolomic approach to identifying platinum resistance in ovarian cancer.J Ovarian Res2015https://conductscience.org/library/papers/25880539PubMed
25264741Combinatorial measurement of CDKN1A/p21 and KIF20A expression for discrimination of DNA damage-induced clastogenicity.Int J Mol Sci2014https://conductscience.org/library/papers/25264741PubMed
24699359Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.PLoS Genet2014https://conductscience.org/library/papers/24699359PubMed
24133631A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Cancer Med2013https://conductscience.org/library/papers/24133631PubMed
24086737Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells.PLoS One2013https://conductscience.org/library/papers/24086737PubMed
24066670Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.J Transl Med2013https://conductscience.org/library/papers/24066670PubMed
23090015Identification and characterization of a 66-68-kDa protein as a methotrexate-binding protein in murine leukemia L1210 cells.Cell Stress Chaperones2013https://conductscience.org/library/papers/23090015PubMed
22986709Polymorphic transporters and platinum pharmacodynamics.Drug Metab Pharmacokinet2013https://conductscience.org/library/papers/22986709PubMed
22691365Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents.J Ovarian Res2012https://conductscience.org/library/papers/22691365PubMed
22459901Contribution of tumoral and host solute carriers to clinical drug response.Drug Resist Updat2012https://conductscience.org/library/papers/22459901PubMed
20815774Overcoming platinum resistance in ovarian carcinoma.Expert Opin Investig Drugs2010https://conductscience.org/library/papers/20815774PubMed

See all 46 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/387221

GET https://conductscience.org/api/papers/v1/387221/cited_by?page=2